# Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease

Study · id `cardio:ct-nct07909915` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07909915](<https://clinicaltrials.gov/study/NCT07909915>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07909915

Browse, organ or system: Brain; Metabolism  
Browse, condition area: Risk and prevention; Stroke; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 178 participants.

## Technical summary

Registry record NCT07909915. Randomized; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 178 participants (planned count; ClinicalTrials.gov record NCT07909915, source copy `cardio:ctgov-nct07909915-2026-11-05`, retrieved 2026-11-18)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07909915, source copy `cardio:ctgov-nct07909915-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT07909915, source copy `cardio:ctgov-nct07909915-2026-11-05`, retrieved 2026-11-18)
- Completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT07909915, source copy `cardio:ctgov-nct07909915-2026-11-05`, retrieved 2026-11-18)
- Countries: Pakistan (ClinicalTrials.gov record NCT07909915, source copy `cardio:ctgov-nct07909915-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07909915-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease
- Condition: Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
- Condition: Stroke (CVA) or TIA
- Condition: Cardio Vascular Disease
- Intervention (Drug): Dose adjustment of statins
- Intervention (Drug): no dose adjustment
- Lead sponsor: Rehman Medical Institute - RMI
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: f5aed13ea2ac0e33c72b9172b7f9ff497e523c27162db1747041e9a37669d7dc
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
